Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
BRIEF REPORT

Platelet-activating immune complexes identified in critically ill COVID-19 patients suspected of heparin-induced thrombocytopenia

Ishac Nazy1,2 | Stefan D. Jevtic1 | Jane C. Moore1 | Angela Huynh1 | James W. Smith1 | John G. Kelton1,2 | Donald M. Arnold1,2,3

1Department of Medicine, Michael G. DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada
2McMaster Centre for Transfusion Research, Hamilton, ON, Canada
3Canadian Blood Services, Hamilton, ON, Canada

Correspondence
Ishac Nazy, Department of Medicine, Michael G. DeGroote School of Medicine, McMaster University, HSC 3H53, 1280 Main Street West, Hamilton, ON L8S 4K1, Canada.
Email: nazii@mcmaster.ca

Funding information
COVID-19 Rapid Research Fund, Grant/Award Number: #C-191-2426729-NAZY; Canadian Institute of Health Research (CIHR)-COVID-19 Immunity Task Force (CITF), Grant/Award Number: #VR2-173204; Ontario Research Fund, Grant/Award Number: 2426729; Academic Health Sciences Organization, Grant/Award Number: HAH-21-02

Abstract

Background: Thrombocytopenia and thrombosis are prominent in coronavirus disease 2019 (COVID-19), particularly among critically ill patients; however, the mechanism is unclear. Such critically ill COVID-19 patients may be suspected of heparin-induced thrombocytopenia (HIT), given similar clinical features.

Objectives: We investigated the presence of platelet-activating anti-platelet-factor 4 (PF4)/heparin antibodies in critically ill COVID-19 patients suspected of HIT.

Patients/Methods: We tested 10 critically ill COVID-19 patients suspected of HIT for anti-PF4/heparin antibodies and functional platelet activation in the serotonin release assay (SRA). Anti-human CD32 antibody (IV.3) was added to the SRA to confirm FcγRIIA involvement. Additionally, SARS-CoV-2 antibodies were measured using an in-house ELISA. Finally, von Willebrand factor (VWF) antigen and activity were measured along with A Disintegrin And Metalloprotease with ThromboSpondin-13 Domain (ADAMTS13) activity and the presence of anti-ADAMTS13 antibodies.

Results: Heparin-induced thrombocytopenia was excluded in all samples based on anti-PF4/heparin antibody and SRA results. Notably, six COVID-19 patients demonstrated platelet activation by the SRA that was inhibited by FcγRIIA receptor blockade, confirming an immune complex (IC)-mediated reaction. Platelet activation was independent of heparin but inhibited by both therapeutic and high dose heparin. All six samples were positive for antibodies targeting the receptor binding domain (RBD) or the spike protein of the SARS-CoV-2 virus. These samples also featured significantly increased VWF antigen and activity, which was not statistically different from the four COVID-19 samples without platelet activation. ADAMTS13 activity was not severely reduced, and ADAMTS13 inhibitors were not present, thus ruling out a primary thrombotic microangiopathy.

Conclusions: Our study identifies platelet-activating ICs as a novel mechanism that contributes to critically ill COVID-19.
INTRODUCTION

Coronavirus disease 2019 (COVID-19) is a highly transmissible viral infection caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and has resulted in a global pandemic.\(^1\)_\(^2\) Critically ill patients with COVID-19 can have prominent coagulation abnormalities, including mild thrombocytopenia and diffuse arterial and venous thrombosis.\(^3\)\(^4\) While the mechanism is unclear, the clinical presentation shares many features of heparin-induced thrombocytopenia (HIT), namely thrombocytopenia and thrombosis during critical illness.\(^7\)

Heparin-induced thrombocytopenia is a prothrombotic disorder that typically presents as thrombocytopenia related to heparin treatment and is associated with a high risk of thrombosis. HIT is caused by IgG-specific antibodies targeting platelet-factor 4 (PF4) that form immune complexes (IC) and cause platelet activation through the Fc\(\gamma\)RIIA receptor.\(^8\)\(^9\) Recent reports have speculated that ICs also contribute to the pathobiology of severe COVID-19.\(^7\) Retrospective analysis has shown that anti-PF4/heparin antibodies are identified more frequently in COVID-19 hospitalized patients compared to the general population.\(^11\) However, it is unclear if these contribute to platelet activation. In this report, we describe platelet-activating ICs in critically ill COVID-19 patients suspected of HIT. These ICs are not formed from IgG-specific anti-PF4/heparin antibodies and occur in conjunction with elevated von Willebrand factor (VWF) and anti-COVID-19 antibodies. Platelet-activating ICs may thus be an additional mechanism contributing to severe COVID-19.

STUDY DESIGN AND METHODS

Blood samples from 10 critically ill patients with COVID-19 were referred to the McMaster Platelet Immunology Laboratory (MPIL) for HIT testing. All samples sent for HIT testing are from patients with medium to high risk of HIT based on clinical presentation, including reduced platelet count, with or without thrombosis. Demographic data were obtained including age, sex, platelet nadir, heparin use, thrombotic event, admission diagnosis, and outcome (where available). Control samples included eight convalescent COVID-19-positive patients, five pre-pandemic HIT-positive samples (HIT), and seven pre-pandemic healthy controls (HC).

Testing for anti-PF4/heparin antibodies was done using an anti-PF4/heparin enzymatic immunoassay (EIA, LIFECODES PF4 enhanced assay; Immucor GTI Diagnostics) for IgG, IgM, and IgA PF4-heparin antibodies. If positive, an in-house, IgG-specific anti-PF4/heparin EIA was performed.\(^12\) All samples were then tested for functional platelet activation in the serotonin release assay (SRA) with heparin (0, 0.1, 0.3, and 100 U/ml) as previously described. An anti-human CD32 antibody (IV.3) was added to the SRA to confirm Fc\(\gamma\)RIIA engagement.\(^13\) Testing for IgG-\(^\_\), IgA-\(^\_\), and IgM-specific antibodies against the receptor-binding domain (RBD) and spike protein of SARS-CoV-2 virus was done using our in-house ELISA, which has a sensitivity of 97.1% and a specificity of 98%.\(^14\)

VWF antigen levels were assessed by the HemosIL von Willebrand Factor antigen automated chemiluminescent immunoassay (Instrumentation Laboratory). VWF activity was measured using the Innovance VWF Ac Assay (OPHL03; Siemens). A Disintegrin And Metalloprotease with ThromboSpondin-13 Domain (ADAMTS13) metalloproteinase activity and anti-ADAMTS13 antibody were tested for all patients, as previously described, to determine whether VWF changes were related to ADAMTS13 activity.\(^15\) All testing was done using plasma from blood collected in sodium citrate. Data represent mean ± standard error of the mean and are analyzed by Student’s t test. Results are considered significant at \(P < .05\).

This study was approved by the Hamilton Integrated Research Ethics Board.

RESULTS AND DISCUSSION

Blood samples were referred to the MPIL for HIT testing from 10 critically ill COVID-19 patients (Table 1). All patients developed thrombocytopenia and had been exposed to heparin. Four patients developed thrombosis, one did not, and data were unavailable for the remaining five. Initial testing for IgG, IgA, and
positive samples, the positive predictive value of HIT is <1.4% and weakly positive (OD405 nm) IgM anti-PF4/heparin antibodies was negative in five samples independent platelet activation excludes HIT in all samples. 13 demonstrated heparin-dependent platelet activation (Figure 1A). 13

This combination of anti-PF4/heparin EIA results with heparin-independent platelet activation excludes HIT in all samples. 13

Of note, six critically ill COVID-19 samples demonstrated significant platelet activation in the absence of heparin (Figure 1A). Platelet activation was inhibited with all heparin concentrations (0.1, 0.3 U, and 100 U/ml), as opposed to the classic, heparin-dependent activation seen in HIT patients (Figure 1A,B). Addition of IV.3 (FcγRIIA inhibitor) inhibited platelet activation, confirming an IgG-specific IC-mediated reaction (Figure 1A,B). Because certain virus-specific antibodies are known to form ICs, we tested for COVID-19 antibodies using our anti-SARS-CoV-2-ELISA. 14 This ELISA is highly sensitive and specific for antibodies against the COVID-19 spike glycoprotein (spike) and RBD located within the spike protein. All six platelet-activating samples contained IgG-specific antibodies against RBD, spike, or both proteins (Figure 1C), while none of the controls had anti-SARS-CoV-2 antibodies. Convalescent plasma from non-critically ill COVID-19 subjects (n = 8) did not activate platelets in the SRA, despite having high titers of anti-SARS-CoV-2 antibodies, indicating that antibodies alone are insufficient for platelet activation (data not shown). A subset of critically ill COVID-19 patient sera thus contains ICs that mediate platelet activation via FcγRIIA signalling.

Immune complexes are known to trigger endothelial cell activation in diseases such as HIT and lupus vasculitis with subsequent VWF release. 17,18 Similarly, increased VWF release is a hallmark of COVID-19 coagulopathy and has been correlated with mortality. 19,20 We therefore tested VWF antigen in our samples, and found markedly elevated levels (range 2.1–10.1 U/ml; mean = 5.9 U/ml; normal range 0.5–1.5 U/ml) compared to healthy controls (range 0.9–1.5 U/ml; mean = 1.2 U/ml; Figure 2A). Ristocetin activity, as a marker of VWF activity, was also significantly increased (range 2.2–8.52 U/ml; mean 4.6 U/ml; normal range 0.8–1.8 U/ml) compared to healthy controls (range 0.53–1.67 U/ml; mean = 1.18 U/ml; Figure 2B). These increases were not significantly different between COVID-19 patients with or without immune complexes. These data confirm elevated VWF in our samples, as has previously been shown.

To determine if this VWF increase was related to ADAMTS13 metalloproteinase function, we tested for ADAMTS13 activity...
and the presence of anti-ADAMTS13 antibody. ADAMTS13 activity was moderately reduced (<40%) in all COVID-19 samples but only severely deficient (<10%) in one (Figure 2C). Only one sample contained anti-ADAMTS13 antibody, which did not correspond to severe ADAMTS13 deficiency (Figure 2D). The elevated VWF is therefore not secondary to severe ADAMTS13 reduction and also confirms that anti-ADAMTS13 antibodies are not responsible for the platelet activation.

We have described our findings in critically ill COVID-19 samples obtained from patients with a clinical suspicion for HIT. Similar to HIT, certain patient samples contain ICs capable of mediating platelet activation. However, in contrast to HIT, COVID-19 ICs are not formed of anti-PF4/heparin antibodies. The lack of anti-PF4/heparin antibodies and presence of heparin-independent SRA activation strongly rules out HIT. Furthermore, these platelet-activating ICs are inhibited by FcγRIIA blockade and heparin, including therapeutic (0.1 and 0.3 U/ml) and high (100 U/ml) doses. Our findings are supported by previous work showing significantly increased platelet apoptosis, secondary to IgG-mediated FcγRIIA signaling, in critically ill COVID-19 patients. It is important to note that the platelet-activating ICs in our cohort were identified using a buffer control (i.e., no addition of heparin). This step should thus be included in all SRA testing, as it can both identify atypical HIT and non-HIT platelet-activating ICs. Together, these observations highlight a novel mechanism for COVID-19 ICs in severe illness.

We also confirm that this mechanism is separate from previously noted coagulopathic changes, namely involving the VWF-ADAMTS13 axis. Prior studies have shown that VWF antigen levels and reduction of ADAMTS-13 activity correlate with disease severity. These changes are also associated with increased mortality, likely secondary to microthrombotic complications. We demonstrate that our observations are not secondary to severe ADAMTS13 activity reduction (<10%) or the presence of anti-ADAMTS13 antibody, as described in thrombotic thrombocytopenic purpura (TTP). This pattern is more consistent with a secondary thrombotic microangiopathy and is likely compounded by the presence of platelet-activating ICs.

One limitation of this study is the inability to characterize the specificity of these platelet-activating ICs. It is possible that the ICs are composed of COVID-19 virus–antibody complexes, similar to that seen with H1N1 viral infection. This is further supported by inhibition with therapeutic heparin, as heparin binds the SARS-CoV-2 RBD to cause a conformational change with altered binding specificity, potentially disrupting the ICs and inhibiting platelet activation.

![Figure 1](https://example.com/figure1.png)

**FIGURE 1** Critically ill coronavirus disease 19 (COVID-19) patients with COVID-19 antibodies contain immune complex (ICs) that are capable of platelet activation in the serotonin release assay (SRA) in a manner that is unique from heparin-induced thrombocytopenia (HIT) ICs. (A) COVID-19 (n = 10) patient sera compared to (B) HIT patient (n = 5) sera, serving as a control, in the SRA. 14C-serotonin release was measured in the absence or presence of increasing heparin doses or with addition of IV.3 (FcγRIIA inhibitor); 14C-serotonin release >20% is positive in the SRA (horizontal dashed line). Most COVID-19 patient sera (n = 6, solid line) demonstrate heparin-independent platelet activation, as opposed to classic HIT controls. Platelet activation was inhibited with IV.3 in both groups. C, IgG, IgA, and IgM COVID-19 antibodies in critically ill COVID-19 patient sera (platelet-activating, n = 6). Antibodies were measured in the SARS-CoV-2 ELISA and include RBD and spike protein specificity. Each symbol represents the same distinct patient result. Values are shown as a ratio of observed optical density to the determined assay cut-off optical density. Values above 1 are considered positive in the SARS-CoV-2 ELISA.
In addition, access to clinical data was limited and so extrapolations cannot be made regarding association with thromboembolic phenomena or additional clinical factors. Regardless, the data presented here outline the characteristics of these ICs and differentiate them from other severe coagulation disorders, including HIT and TTP.

We thus propose a model whereby certain critically ill COVID-19 patients feature a novel IC-mediated thrombotic microangiopathy that is characterized by significant platelet activation. These ICs can produce a highly prothrombotic state resembling HIT but with unique platelet-activating properties.

ACKNOWLEDGMENTS

Funding support for this work was provided by a grant from the Ontario Research Fund (ORF #2426729), COVID-19 Rapid Research Fund (V#C-191-2426729-NAZY) and Canadian Institute of Health Research (CIHR)-COVID-19 Immunity Task Force (CITF) (#VR2-173204) awarded to Dr. Ishac Nazy, and Academic Health Sciences Organization (HAHSO) grant awarded to Dr. Donald M. Arnold (#HAH-21-02).

CONFLICTS OF INTEREST

The authors declare no competing financial interests.

AUTHOR CONTRIBUTIONS

I. Nazy designed the research, analyzed and interpreted data, and wrote the manuscript. S.D. Jevtic, J.C. Moore, A. Huynh, and J.W. Smith carried out the described studies, analyzed data, and wrote the manuscript. J.G. Kelton and D.M. Arnold designed the research and wrote the manuscript. All authors reviewed and approved the final version of the manuscript.

ORCID

Ishac Nazy https://orcid.org/0000-0002-5695-4343
Stefan D. Jevtic https://orcid.org/0000-0002-0806-9833

TWEET

Ishac Nazy @ishagaby
Stefan D. Jevtic @stefan_d_jevtic

REFERENCES

1. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease in China. N Engl J Med. 2019;2020(382):1708-1720. https://doi.org/10.1056/NEJMoa2002032
2. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497-506. https://doi.org/10.1016/s0140-6736(20)30183-5
3. Helms J, Tacquard C, Severac F, et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med. 2020;46:1089-1098. https://doi.org/10.1007/s00134-020-06062-x
4. Klok FA, Krup M, van der Meer NJM, et al. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: an updated analysis. Thromb Res. 2020;191:148-150. https://doi.org/10.1016/j.thromres.2020.04.041
5. Nahum J, Morichau-Beauchant T, Daviaud F, et al. Venous thrombosis among critically ill patients with coronavirus disease 2019 (COVID-19). JAMA Netw Open. 2020;3:e2010478. https://doi.org/10.1001/jamanetworkopen.2020.10478
6. Litjios JF, Leclerc M, Chochois C, et al. High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients. *J Thromb Haemost.* 2020;18:1743-1746. https://doi.org/10.1111/jth.14869

7. Warkentin TE, Kaatz S. COVID-19 versus HIT hypercoagulability. *Thromb Res.* 2020;196:38-51. https://doi.org/10.1016/j.thromres.2020.08.017

8. Chong BH, Fawaz I, Chesterman CN, Berndt MC. Heparin-induced thrombocytopenia: mechanism of interaction of the heparin-dependent antibody with platelets. *Br J Haematol.* 1989;73:235-240.

9. Kelton JG, Sheridan D, Santos A, et al. Heparin-induced thrombocytopenia: laboratory studies. *Blood.* 1988;72:925-930.

10. Roncati L, Ligabue G, Fabbiani L, et al. Type 3 hypersensitivity in heparin-induced thrombocytopenia. *Clin Immunol.* 2020;217:e108487. https://doi.org/10.1016/j.clim.2020.108487

11. Warrior S, Behrens E, Gezer S, Venugopal P, Jain S. Heparin induced thrombocytopenia. *Am J Hematol.* 2020;95:161-167. https://doi.org/10.1046/j.1365-2141.1996.d01-1876.x

12. Horsewood P, Warkentin TE, Hayward CP, Kelton JG. The epitope specificity of heparin-induced thrombocytopenia. *Br J Haematol.* 1996;95:161-167. https://doi.org/10.1046/j.1365-2141.1996.01876.x

13. Sheridan D, Carter C, Kelton JG. A diagnostic test for heparin-induced thrombocytopenia. *Blood.* 1986;67:27-30.

14. Huynh A, Arnold DM, Kelton JG, et al. Development of a serological assay to identify SARS-CoV-2 antibodies in COVID-19 patients. *medRxiv* Preprints. 2020. https://doi.org/10.1101/2020.09.11.20192690

15. Studt JD, Budde U, Schneppenheim R, et al. Quantification and facilitated comparison of von Willebrand factor multimer patterns by densitometry. *Am J Clin Pathol.* 2001;116:567-574. https://doi.org/10.1309/75CQ-V7UX-4QX8-WXE7

16. Warkentin TE, Sheppard JL, Moore JC, Sigouin CS, Kelton JG. Quantitative interpretation of optical density measurements using PF4-dependent enzyme-immunoassays. *J Thromb Haemost.* 2008;6:1304-1312. https://doi.org/10.1111/j.1538-7836.2008.03025.x

17. Blank M, Shoefield Y, Tavor S, et al. Anti-platelet factor 4/heparin antibodies from patients with heparin-induced thrombocytopenia provoke direct activation of microvascular endothelial cells. *Int Immunol.* 2002;14:121-129. https://doi.org/10.1093/intimm/m14.2.121

18. Sun W, Jiao Y, Cui B, Gao X, Xia Y, Zhao Y. Immune complexes activate human endothelium involving the cell-signaling HMGB1-RAGE axis in the pathogenesis of lupus vasculitis. *Lab Invest.* 2013;93:626-638. https://doi.org/10.1038/labinvest.2013.61

19. Goshua G, Pine AB, Meizlish ML, et al. Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study. *Lancet Haematol.* 2020;7:e575-e582. https://doi.org/10.1016/s2352-3026(20)30216-7

20. Henry BM, Benoit SW, de Oliveira MHS, Lippi G, Favaloro EJ, Benoit JL. ADAMTS13 activity to von Willebrand factor antigen ratio predicts acute kidney injury in patients with COVID-19: Evidence of SARS-CoV-2 induced secondary thrombotic microangiopathy. *Int J Lab Hematol.* 2020. https://doi.org/10.1111/jjh.13415

21. Altheraus K, Marini I, Zlamal J, et al. Antibody-induced procoagulant platelets in severe COVID-19 infection. *Blood.* 2020;137:1061-1071. https://doi.org/10.1182/blood.2020008762

22. Warkentin TE, Arnold DM, Nazi I, Kelton JG. The platelet serotonin-release assay. *Am J Hematol.* 2015;90:564-572. https://doi.org/10.1002/ajh.24006

23. Mancini I, Baronciani L, Artoni A, et al. The ADAMTS13-von Willebrand factor axis in COVID-19 patients. *J Thromb Haemost.* 2020;19:513-521. https://doi.org/10.1111/jth.15191

24. Arnold DM, Patrichin CJ, Nazi I. Thrombotic microangiopathies: a general approach to diagnosis and management. *CMAJ.* 2017;189:E153-E159. https://doi.org/10.1503/cmaj.160142

25. Doevelaar AA, Bachmann M, Hoelzer B, et al. COVID-19 is associated with relative ADAMTS13 deficiency and VWF multimer formation resembling TTP. *medRxiv* Preprints. 2020. https://doi.org/10.1101/2020.08.23.20177824

26. Boilard E, Pare G, Rousseau M, et al. Influenza virus H1N1 activates platelets through FcgammaRIIA signaling and thrombin generation. *Blood.* 2014;123:2854-2863. https://doi.org/10.1182/blood-2013-07-515536

27. Yang Y, Du Y, Kaltashov IA. The utility of native MS for understanding the mechanism of action of repurposed therapeutics in COVID-19: heparin as a disruptor of the SARS-CoV-2 interaction with its host cell receptor. *Anal Chem.* 2020;92:10930-10934. https://doi.org/10.1021/acs.analchem.0c02449

How to cite this article: Nazy I, Jevtic SD, Moore JC, et al. Platelet-activating immune complexes identified in critically ill COVID-19 patients suspected of heparin-induced thrombocytopenia. *J Thromb Haemost.* 2021;19:1342-1347. https://doi.org/10.1111/jth.15283